Drug Database
YE

yellow fever vaccine (Arilvax)

✓ Approved

Novartis AG · Vaccine · Vaccine

What is yellow fever vaccine?

yellow fever vaccine is a vaccine developed by Novartis AG. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.

Drug Profile

Brand NamesArilvax
CompanyNovartis AG
Drug ClassVaccine, Large Molecules
RouteInjectable (Others), Subcutaneous Injection
StatusApproved

Therapeutic Indications

yellow fever vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsYellow fever✓ Approved

Related Research Articles

PubMedJournal of clinical and translational science2026-07-17

A machine learning approach to identify at-risk populations for yellow fever vaccination.

Farnsworth Madison M, Botnar Kostiantyn K, Nguyen Justin T JT, Watson Riley K RK et al.

Vaccinations play a crucial role in public and personal health. Vaccines such as the Yellow Fever 17D vaccine are effective at preventing disease and provide lifelong immunity with few adverse events. Leveraging the increase in electronic medical records and the widespread use of machine learning algorithms in healthcare, this study aims to investigate and develop an algorithmic framework for analyzing clinical data on Yellow Fever 17D vaccinations in order to predict at-risk populations for adverse events following immunizations. This research incorporates parameters from the patient's medical history and demographic information. To build our analytic framework, we tested five machine learning algorithms: random forest, gradient boost, logistic regression, XGBoost, and Bernoulli naïve Bayes. We cleaned and managed the datasets through EHRchitect software. We assessed the performance of the algorithms using standard metrics, including precision, recall, F1-scores, accuracy, and the area under the receiver operating characteristic curve. Additionally, we implemented population sampling to mitigate potential biases common in clinical data and performed parameter ranking analysis to identify the most influential features in classifying patient reaction outcomes. We found that logistic regression produced the highest performance, and through hyperparameter optimization, we developed a framework with precision, accuracy, and ROC scores of 87.7%, 99.0%, and 0.818, respectively. In conclusion, this study examined five modeling algorithms to establish a framework for analyzing real-world data and to predict at-risk populations for adverse events following immunization. We incorporated a logistic regression algorithm to assess our clinical data to achieve a high-precision performance model for classifying patient predictions.

PubMedBMJ open2026-07-17

Carbon emissions of a vaccine trial implemented in Uganda: retrospective assessment to identify actions to enhance researchers' environmental responsibilities.

Juan-Giner Aitana A, Charrier Maëlle M, Langendorf Céline C, Namulwana Maria Louise ML et al.

To estimate the carbon footprint of a vaccine trial conducted in Uganda and to identify opportunities to reduce greenhouse gas emissions in future trials. Retrospective carbon footprint assessment of all trial-related activities conducted in Uganda (ClinicalTrials.gov ID NCT02991495), following the Greenhouse Gas Protocol and the guidance provided by the Low Carbon Clinical Trials Group. The activities related to the yellow fever vaccine fractional dose trial implemented in Mbarara, with contributions from international collaborators. The study assessed processes; no participants have been included. Trial activities were retrospectively quantified and converted into a greenhouse gas estimate using publicly available emission factors. The boundaries of the study were defined to cover the set-up, implementation and close-out phases. Emissions were categorised by source, including personnel, travel, medical supply and laboratory. The vaccine trial produced an estimated 224.66 tonnes of carbon dioxide equivalent (tCO2e). The largest emission category was related to the research centres, accounting for 78.80 tCO2e (35.07%), with the Mbarara research centre representing 75.74 tCO2e (32.38%), including commuting (21.01 tCO2e), waste disposal (19.31 tCO2e), goods and services (18.66 tCO2e) and energy (13.75 tCO2e). International travel, including air, non-air travel and accommodation accounted for 59.37 tonnes CO2e (26.43%), with the majority attributed to air travel (53.60 CO2e). Additional contributors included road travel by trial team and participants' travel to attend trial's visits. The storage of samples at -80°C in ultra-dry freezers was not a significant contributor due to the low volume of samples stored. However, important differences were observed in sample storage emissions between settings that relied more heavily on oil-based electricity and those with greater dependence on hydroelectric power. This study highlights multiple opportunities to reduce the carbon emissions of clinical trials. These include already recognised actions such as higher use of solar energy and reduction of international travel. Nevertheless, to improve sustainability of trials, attention should be given to all controllable processes across the trial lifecycle and not solely to the main drivers of emissions. For this, environmental considerations should be present from the initial trial conception phase, involving for instance decisions about the number of trial visits and where these are conducted and taking rational decisions about the long-term storage of samples.

PubMedClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026-07-17

Artificial Intelligence Across the Vaccine Clinical Trial Lifecycle: Evidence, Readiness, and Guardrails.

Idriss Jad J, Kalash Suha S, Faraj Jana Abu JA, Nolan Lauren L et al.

Artificial intelligence (AI) is increasingly being used to support clinical research, but its value in vaccine clinical trials requires careful evidence-based assessment. Vaccine trials pose distinctive challenges, including high safety expectations in healthy participants, evolving pathogen exposure and baseline immunity, incomplete correlates of protection, applicability of findings to intended-use populations, and intense public scrutiny. We conducted a structured, vaccine-focused narrative review of AI applications across the vaccine trial lifecycle, supplemented by targeted clinical trial and vaccine pharmacovigilance studies with directly transferable methods. In the combined evidence base, evidence is strongest for operational uses, particularly recruitment, eligibility screening, trial matching, and risk-based monitoring. Applications to immune-response interpretation, correlates of protection, and vaccine safety surveillance are promising but remain less prospectively validated. Responsible adoption should be guided by intended tool use, evidence of strength, data governance, regulatory expectations, and preservation of human scientific and safety judgment.

PubMedEuropean journal of case reports in internal medicine2026-07-17

Protracted Febrile Myalgia Syndrome as Initial Presentation of Familial Mediterranean Fever in a Patient of Northern European Extraction Thought to have Ulcerative Colitis.

Ammari Stephanie S, Stein Daniel D, Ibrahim Nawras N

Protracted febrile myalgia syndrome is a rare vasculitic manifestation of familial Mediterranean fever that presents as the initial familial Mediterranean fever manifestation in one-third of cases. While familial Mediterranean fever is classically autosomal recessive and associated with Mediterranean ancestry, the p.Met694del variant demonstrates autosomal dominant inheritance with a Northern European founder effect. MEFV-related enterocolitis can produce histologic features indistinguishable from inflammatory bowel disease. A 24-year-old European American man with no Mediterranean, Middle Eastern or Armenian ancestry, with biopsy-confirmed ulcerative colitis on upadacitinib, presented with six weeks of high-grade fevers, incapacitating myalgias, a 30-pound weight loss and pericardial effusion. Faecal calprotectin was markedly elevated (>8,000 μg/g) without gastrointestinal symptoms. Inflammatory markers were noticeably elevated with normal creatine kinase; extensive infectious and malignancy workup was negative. Bone marrow biopsy demonstrated focal haemophagocytosis without malignancy. Dramatic improvement occurred within 24-48 hours of corticosteroid initiation. Genetic testing revealed heterozygous p.Met694del, confirming autosomal dominant familial Mediterranean fever. At six-month follow-up on colchicine monotherapy without inflammatory bowel disease-directed therapy, inflammatory markers, faecal calprotectin and pericardial effusion had completely normalised, fulfilling Tel Hashomer criteria. This case highlights protracted febrile myalgia syndrome as an under-recognised initial presentation of autosomal dominant familial Mediterranean fever in non-Mediterranean populations. Colchicine-responsive normalisation of faecal calprotectin raises the possibility that MEFV-mediated enterocolitis contributed to intestinal inflammation initially attributed to ulcerative colitis. Early recognition enables amyloidosis prevention and essential genetic counselling for first-degree relatives. Protracted febrile myalgia syndrome - prolonged fever, incapacitating myalgia and normal creatine kinase, should prompt consideration of familial Mediterranean fever regardless of ancestry, as the p.Met694del variant follows autosomal dominant inheritance with a Northern European founder effect.Colchicine-responsive normalisation of faecal calprotectin (>8,000 to normal) without inflammatory bowel disease-directed therapy in a patient with biopsy-confirmed ulcerative colitis and a pathogenic MEFV variant, raises the possibility that MEFV-mediated enterocolitis contributed to intestinal inflammation initially attributed to inflammatory bowel disease, a distinction with direct therapeutic implications.Autosomal dominant MEFV variants carry critical implications for family counselling: first-degree relatives have a 50% risk of inheriting the variant and developing familial Mediterranean fever, including phenotype II amyloidosis (renal amyloidosis without preceding typical attacks).

PubMedIranian journal of nursing and midwifery research2026-07-17

Investigate the Relationship Between Receiving the COVID-19 Vaccine and Menstrual Disorders among Females of Reproductive Age in Jeddah, Saudi Arabia.

Esheaba Ola M OM, Fouly Howieda A HA, Kassem Fathia K FK

There are many physical side effects of the COVID-19 vaccine, including unexpected changes occurring in menstrual bleeding. This study aimed to assess the relation between the COVID-19 vaccine and disorders in menstruation among females of reproductive age. Participants were recruited from a nonprobability snowball sampling targeted at females who are living in Jeddah city between March 2022 and August 2022, Kingdom of Saudi Arabia (KSA). A quantitative cross-sectional design was utilized to conduct the study, a nonexperimental design based on a single observation point. The sample size is estimated by the G*Power software to be 180, considering missed cases, it increased to 197. Regarding menstrual changes, n = 86 (43.65%) experienced a delay, and about one-third reported an earlier menstruation cycle. A significant relationship is observed between nationality, occupation, and changes in period (t = 3.89, P < 0.001 and t = -2.94, P < 0.004). There is no significant difference in the occurrence of complications among the different vaccine types. Receiving the COVID-19 vaccine was strongly linked with unexpected disturbance in menstruation among the studied group, from simple menstrual irregulates to reported amenorrhea after receiving the booster doses. However, the occurrence of menstrual cycle delays was not linked to the vaccine type. Further studies should be done to investigate each type of vaccine specifically to determine if the type of vaccine affects the reproductive function generally not only the menstrual cycle, in a larger survey for more generalizability.

PubMedFrontiers in public health2026-07-17

Reframing vaccine narrative: a co-production study of a media campaign intervention to address childhood vaccine hesitancy among Nigerian parents and caregivers.

Ike Tarela Juliet TJ, Jidong Dung Ezekiel DE, Obi Callistar Kidochukwu CK, Ntaji Maureen Iru MI et al.

Childhood vaccine hesitancy is a public health concern. Nigeria is one of the countries with the highest rates of zero-dose childhood vaccination. This study makes an original contribution by adopting a co-production approach underpinned by interpretative phenomenological analysis (IPA) to meaningfully inform the co-production of a media campaign intervention with Nigerian parents/ caregivers whose child(ren) are not, or only partially, up to date with routine immunizations aimed at reducing childhood vaccine hesitancy and promoting uptake. A total of 10 parents or caregivers whose children were not up to date with their vaccinations were recruited for the study and participated in a focus group discussion. Data were analyzed using IPA. The findings reveal that hostility, misinformation, and the breakdown of trust in vaccines, alongside faith, tradition, and the lived logic of alternative protection, intersect to exacerbate hesitancy. The findings also reveal that clarity, reassurance, and empowerment in vaccine communication, underpinned by gendered voices, can build trust in vaccine messaging and encourage uptake. The study offers important insights for policymakers and public health communication strategies, underscoring the need for culturally appropriate media campaign interventions that address vaccine-related concerns and foster uptake.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about yellow fever vaccine